Latest Commercialisation News

Syntara Limited has unveiled encouraging interim Phase 2a data for SNT-5505, an add-on therapy targeting myelofibrosis patients with suboptimal response to ruxolitinib. The data highlight meaningful symptom relief and spleen volume reduction, positioning the drug as a potential game-changer in a challenging treatment landscape.

Control Bionics is on track for its strongest financial year yet, driven by robust US and Australian sales and promising global trials of its NeuroStrip® device.

HITIQ has partnered exclusively with Shock Doctor to launch the PROTEQT instrumented mouthguard, aiming to transform concussion management worldwide. The company also initiates a $2.92 million rights issue to fuel this ambitious rollout.

SSH Group has raised $2.75 million in a placement anchored by mining sector heavyweight Ross Stewart Norgard, aiming to accelerate its mining services expansion in Western Australia.

Brazilian Rare Earths has successfully produced high-purity mixed-rare-earth carbonate and uranium yellowcake from its Monte Alto Project, marking a key milestone in its integrated supply chain ambitions.

Nanoveu Limited has locked in a $500,000 funding guarantee through an options underwriting agreement, underpinning its push to commercialise cutting-edge semiconductor and 3D visualisation technologies.

EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.

Felix Gold Limited has launched field exploration and development at its Treasure Creek Antimony Project in Alaska, aiming for potential antimony concentrate production by late 2025. The company is progressing drilling, environmental studies, and engineering design to support a feasibility study and permitting.

Pure Hydrogen Corporation has secured a 15-year Potential Commercial Area approval and extended its ATP 927 permit for the Windorah Gas Project, marking a critical regulatory milestone ahead of its planned spinout.

Blue Star Helium has wrapped up its 2025 Galactica drilling campaign with strong results from six wells, setting the stage for commercial helium production in the second half of 2025.

AnteoTech Ltd has completed a strategic review that refocuses its business on commercialising existing products, delivering $1.6 million in annual cost savings and expanding its sales pipeline in battery and life sciences markets.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.